CDK9-IN-46 (Compound Formula I) is a CDK9 inhibitor. CDK9-IN-46 can be used for the research of cancer.

CDK2-IN-21 (example 30) is a potent cyclin-dependent kinase 2 (CDK2) inhibitor with an IC50 of 0.24 µM. CDK2-IN-21 can be used for cancer research.

CDC14A/B-IN-2, phosphotyrosine mimetic, is a competitive human CDC14A/B phosphatase inhibitor with IC50 values of 10.4 and 11.2 μM, and Ki values of 5.8 and 7.3 μM. CDC14A/B-IN-2 shows at least 20-fold selectivity over other protein tyrosine phosphatases. CDC14A/B-IN-2 can be used for the research of cancer.

CCR2 antagonist 6 (Example 98) is a CCR2 antagonist (Kb: 0.215 μM for CCR2, 0.174 μM for hCCR2B). CCR2 antagonist 6 can be used in the research of inflammation and autoimmune diseases.

CCL17-IN-2 (Compound Ex.128) is a CCL17 secretion inhibitor with an EC50 of 0.3 nM. CCL17-IN-1 can be used in the research of autoimmune diseases, dermatological conditions, and respiratory disorders.

CC-11 is an orally active small molecule drug conjugate (SMDC) that links the PI3K/mTOR inhibitor with the extracellular heat shock protein 90 (EHSP90) targeting ligand through a cleavable linker. CC-11 exhibits strong HSP90 binding activity (IC50 = 15 nM) and inhibits PI3Kα kinase activity (IC50 = 0.54 nM). CC-11 has anti-proliferative activity against colon cancer cells. CC-11 shows significant efficacy in the HCT-116 xenograft tumor model. CC-11 can be used for research on colon cancer.

CBP/p300/BRD4 ligand-1 is a small-molecule inhibitor targeting CBP, p300, and BRD4. CBP/p300/BRD4 ligand-1 competitively binds to the functional domains of target proteins without disrupting key interactions. CBP/p300/BRD4 ligand-1 can be used for the construction of dual-target PROTAC degraders in studies related to prostate cancer and other cancers.

CBP/p300 ligand-Linker Conjugate 3 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for CBP/p300 and a PROTAC linker, which recruits E3 ligases. CBP/p300 ligand-Linker Conjugate 3 can be used for synthesis of PROTAC CBP/P300 Degrader-2.

Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research.

Carboxyatractyloside (CATR) is a tight-binding inhibitor of adenine nucleotide translocase, and represents the major toxic component of Xanthium sibiricum. Carboxyatractyloside competes with ADP for binding to the translocase, blocks the translocation of ADP/ATP across the inner mitochondrial membrane, and thereby inhibits ADP-stimulated respiration. In the presence of Cyclosporin A, Carboxyatractyloside still induces permeability transition in liver mitochondria of aged rats, exhibiting significant hepatotoxicity and nephrotoxicity. Carboxyatractyloside is widely used in studies related to hepatotoxicity, nephrotoxicity and Alzheimer's disease.

Carbiphene is a GABAA receptor allosteric modulator. Carbiphene inhibits [35S] TBPS binding and enhances [3H] muscimol binding on rat forebrain membranes, acting on specific GABAA receptor subsets. Carbiphene can be used in research related to schizophrenia.

CaMKII-IN-3 (Example 321) is a CaMKII inhibitor with an IC50 of less than 10 nM. CaMKII-IN-3 can be used for the study of heart diseases.

CAD204520 dihydrochloride, a SERCA inhibitor (IC50 = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 dihydrochloride can be used for T-ALL and MCL research.

CAB7-3 is an orally active HBV capsid assembly modulator (CAM). CAB7-3 exhibits an exceptional antiviral efficacy reducing HBV DNA with an EC50 = 70 nM, CC50 = 32.3 μM in HepDES19 cells. CAB7-3 exhibits significant anti-HBV activity in HBV-integrated HepDES19 (EC50 = 70 nM), HepAD38 (EC50 = 1 nM) and HBV-infected HLCZ01 cells (EC50 = 2 nM), respectively. CAB7-3 effectively reduces Hepatic HBV core protein levels and suppresses viral replication in vivo. CAB7-3 demonstrates a favorable drug-like and safety profile. CAB7-3 can be used for Hepatitis B Virus (HBV) research.

C14-Tri-LAN-Gly is a highly selective and potent NOD1 agonist. C14-Tri-LAN-Gly activates NOD1. C14-Tri-LAN-Gly inhibits the expression of cleaved-caspase3. C14-Tri-LAN-Gly upregulates A20 expression. C14-Tri-LAN-Gly protects mice from lethal hepatitis by inhibiting hepatocyte Apoptosis. C14-Tri-LAN-Gly inhibits osteoblastogenesis and promots osteoclastogenesis.

BRL 34778 is a potent, selective and orally active dopamine D2 receptor antagonist with a Ki of 2.14 nM. BRL 34778 exhibits antipsychotic activity with low activity for extrapyramidal effects and sedation. BRL 34778 can be used for the research of neurological disease, such as schizophrenia.

Brigimadlin (BI 907828) enantiomer is the Brigimadlin enantiomer. Brigimadlin is an MDM2 inhibitor with anti-cancer activity.

BRD3 ligand-1 is a target protein ligand that can be used for the synthesis of PROTACs, such as PROTAC BRD3 degrader-1.

BMS-442606, the S-enantiomer of 6-hydroxybuspirone (6OHB), is an orally active 5-HT1A partial agonist. BMS-442606 can be used for generalized anxiety disorder (GAD) research.

BMS-181885 is a selective 5-HT1 receptor agonist and a ligand for 5-HT1B/1D receptors. BMS-181885 exhibits anti-migraine activity. BMS-181885 can be used in the research of neurological diseases such as migraine.

BMS-159 is an orally active, direct phosphate prodrug of BMS-135. BMS-135 is a potent ATP-competitive inhibitor of CK2. BMS-159 can be used in the research of neurological disorders and tumors.

BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection.

BI-135585 hydrate is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC50 of 13 nM. BI-135585 hydrate exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 hydrate can be used for type 2 diabetes research.

BF-175 is a selective SIRT1 agonist. BF175 increases SIRT1-mediated activation of PGC1-α, induces Apoptosis, induces Autophagy and inhibits SREBP activity. BF-175 protects against high glucose-mediated mitochondrial injury. BF-175 attenuates diabetic kidney disease progression. BF175 inhibits endometrial carcinoma.

Betamethasone succinate (NSSL-BMS) is a nano-formulation that can cross the blood-brain barrier. Betamethasone succinate is prepared by encapsulating the Betamethasone semi-succinate in PEG-liposomes. Betamethasone succinate utilizes the enhanced permeation and retention effects of liposomes to target and deliver the potent glucocorticoid to the inflammatory sites. Betamethasone succinate inhibits the secretion of pro-inflammatory cytokines (such as TNF-α and IL-6) while maintaining the level of anti-inflammatory cytokine TGF-β. Betamethasone succinate can be used in the research of arthritis and cerebral malaria.

BE2012, SR8278 derivative, is a potent and selective REV-ERBα/β Antagonist with EC50 values of 0.285 and 0.346 μM. BE2012 binds to the ligand-binding domain (LBD) of REV-ERB, preventing the receptor from recruiting co-inhibitory factors and thereby releasing the transcriptional repression on downstream target genes. BE2012 can upregulate the expression of myogenic transcription factors Myf5 and Myod, promoting muscle regeneration and repair in acute muscle injury micemodels.

BCX-5 (PD 141955) is an orally active inhibitor of purine nucleoside phosphorylase (PNP) with a Ki of 0.08 μM. BCX-5 can inhibit cell proliferation and mixed lymphocyte reaction. BCX-5 can increase plasma inosine and guanosine levels. BCX-5 can be used for the research of immunology.

Aβ/tau aggregation-IN-4 (Compound D21) is an Aβ/tau aggregation inhibitor. Aβ/tau aggregation-IN-4 promotes the degradation of Aβ40/42 (Aβ40, IC50 = 2.151 μM; Aβ42, IC50 = 3.622 μM). Aβ/tau aggregation-IN-4 shows selective AChE inhibition (IC50: 5.56 μM). Aβ/tau aggregation-IN-4 inhibits MAO-A and MAO-B with IC50s of 0.59 μM and 0.09 μM, respectively. Aβ/tau aggregation-IN-4 suppresses intracellular ROS levels. Aβ/tau aggregation-IN-4 can be used in the research of Alzheimer's disease.

Aβ aggregation-IN-4 can alleviate the neurotoxicity of amyloid-β protein (Aβ) and significantly reduce the level of oligomeric complexes of Aβ (Aβ-OCs). Aβ aggregation-IN-4 does not decrease the level of amyloid-β protein (Aβ). Aβ aggregation-IN-4 attenuates Aβ oligomerization and prevents oligomer-induced death of primary cortical neurons. Aβ aggregation-IN-4 can be used for the study of Alzheimer’s disease (AD).

Azimexon (BM 12.531) is an orally active immunomodulator with radioprotective and antitumor activities. Azimexon prolongs survival in multiple mouse models, enhances immunity and hematopoiesis, and alleviates radiation injury and tumor metastasis. Azimexon causes reversible hemolytic anemia in rats and dogs, and exerts therapeutic activity against adjuvant-induced arthritis in rats. Azimexon can be used for the research of lung carcinoma, leukemia, multiple myeloma, lung tumor, arthritis, breast cancer and AIDS‑related complex.